The health claim will give dietary supplement manufacturers an added edge, Enzymotec said.
Enzymotec will be able to use blood pressure-related health claims in relation to K-Real, after it became the first brand of pure krill oil in Europe to meet the European Union’s (EU) criteria for making low-sodium claims.
The news means that dietary supplement companies looking for an edge in the European market will now be able to make on-pack claims about blood pressure when incorporating K-Real into their products.
K-Real is produced using Enzymotec’s proprietary multi-stage oil extraction process, which results in lower sodium levels than other krill oils and guarantees a high quality oil with superior organoleptic properties. The claim approved by the EU is in relation to the positive effect that reduced consumption of sodium has on the maintenance of normal blood pressure.
High sodium intake is associated with higher blood pressure, which is the leading cause of cardiovascular disease, particularly strokes and heart attacks, Enzymotec claimed.
Of the newly approved health claim, Enzymotec president and CEO Dr Ariel Katz said: “This benefit is exclusive to K-Real. No other krill oil offers sodium levels as low as ours does, creating an opportunity for dietary supplement manufacturers and marketers to give their products a unique selling point that will be compelling to their consumers.
“The omega-3 supplements market is highly competitive and a tough space to operate in. But with its unique low sodium benefit, K-Real is an unbeatable choice of ingredient for manufacturers and brands seeking a powerful proposition that will ensure their products stand out on store shelves.”
© FoodBev Media Ltd 2024